2023 年第一季度报告 证券代码：688067 证券简称：爱威科技 爱威科技股份有限公司 2023 年第一季度报告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示 公司董事会、监事会及董事、监事、高级管理人员保证季度报告内容的真实、准确、完整，不存 在虚假记载、误导性陈述或重大遗漏，并承担个别和连带的法律责任。 公司负责人、主管会计工作负责人及会计机构负责人（会计主管人员）保证季度报告中财务信息 的真实、准确、完整。 第一季度财务报表是否经审计 □是 √否 一、 主要财务数据 (一)主要会计数据和财务指标 单位：元 币种：人民币 | 项目 | 本报告期 | 本报告期比上年 同期增减变动幅 | | --- | --- | --- | | | | 度(%) | | 营业收入 | 40,898,718.07 | -11.24 | | 归属于上市公司股东的净利润 | 2,145,251.44 | -63.26 | | 归属于上市公司股东的扣除非经常 | -1,568,972.31 | -138.65 | | 性损益 ...

Financial Performance - The company's operating revenue for 2022 was ¥196,774,016.32, a decrease of 6.60% compared to ¥210,668,650.51 in 2021[21]. - The net profit attributable to shareholders for 2022 was ¥17,973,042.73, down 42.53% from ¥31,275,040.94 in the previous year[21]. - The net profit attributable to shareholders after deducting non-recurring gains and losses was ¥6,272,486.25, a decline of 73.85% from ¥23,985,348.09 in 2021[21]. - The cash flow from operating activities for 2022 was ¥29,739,892.63, a decrease of 36.97% compared to ¥47,185,681.68 in 2021[21]. - The gross profit margin for the main business decreased by 5.32 percentage points to 53.49%[90]. - The company's R&D expenses increased by 6.01% to CNY 33,078,377.41, reflecting a commitment to ongoing research and development[88]. - The company reported a significant increase in revenue, achieving a total of $500 million for the fiscal year, representing a 25% year-over-year growth[187]. - The company reported a net profit margin of 12%, up from 10% in the previous quarter, indicating improved financial health[135]. Dividend Distribution - The proposed cash dividend distribution is RMB 1.00 per 10 shares, totaling RMB 6,800,000.00, which accounts for 37.83% of the net profit attributable to ordinary shareholders for 2022[5]. - The profit distribution plan is subject to approval at the 2022 annual general meeting[5]. - The company emphasizes a stable profit distribution policy, balancing operational conditions and sustainable development[155]. Corporate Governance - The company does not have any special arrangements for corporate governance[8]. - The company has established a scientific and standardized corporate governance structure, complying with relevant laws and regulations[126]. - The company did not experience any major violations or defects in its governance practices during the reporting period[126]. - The company’s governance practices align with the requirements set by the China Securities Regulatory Commission[126]. - The company has established measures to stabilize its stock price if the closing price falls below the latest audited net asset per share for 20 consecutive trading days[197]. Research and Development - The company aims to enhance its research and development capabilities in molecular diagnostics and immunodiagnostics to improve diagnostic accuracy and efficiency[14]. - The total R&D investment for the year reached 34.98 million, a 12.09% increase compared to the previous year, with R&D expenses accounting for 17.77% of total revenue[63]. - The company is committed to continuous research and development to maintain its technological leadership in the medical testing field[53]. - The company is focused on original innovation and technology integration to meet market demands and enhance its competitive edge[53]. Market Expansion - The company is exploring potential market expansion opportunities both domestically and internationally to increase its market share[14]. - The company plans to enhance its product offerings in the primary healthcare market, focusing on AI-assisted diagnostic products[116]. - The company aims to expand its sales channels, including online and offline strategies, to increase market share[117]. - The company is actively expanding its product lines and enhancing its technological capabilities to maintain its competitive edge in the market[75]. Product Development - The company completed multiple new product developments, including automated inspection products covering various clinical specimen testing fields[33]. - The company has developed a urine analysis technology that automates the review of abnormal indicators, improving analysis accuracy and reducing the workload of operators[55]. - The company has introduced multiple home-use POCT products, including urine and fecal tests, with some achieving small-scale sales, targeting the grassroots and civilian medical markets as key growth areas[118]. - The company is developing multi-functional testing instruments capable of analyzing various samples, with a total investment of 940 million and 39.24 million invested in the current period[68]. Risk Management - The company has detailed the major risks and countermeasures in the report, which can be found in the section on risk factors[4]. - The company faces risks related to new product development, including long development cycles and regulatory approval processes that can take several years[82]. - The company is exposed to potential price declines due to rapid technological advancements and government price controls in the medical testing sector[83]. Intellectual Property - A total of 228 patents were obtained, including 77 domestic invention patents and 13 foreign invention patents, indicating strong intellectual property protection[34]. - The company has implemented multiple measures to protect intellectual property rights and has established an information security management system to safeguard its information[183]. Customer Relations - The company has established a strong brand reputation and customer loyalty through its commitment to product quality and after-sales service[79]. - Customer satisfaction ratings have improved to 90%, reflecting the success of recent service enhancements[135]. Financial Management - The company has established a detailed management system for the use of raised funds to ensure compliance and protect investor interests[200]. - The company will manage raised funds in a dedicated account to ensure they are used legally and appropriately[200]. - The company has implemented cost-cutting measures aimed at reducing operational expenses by 5% in the upcoming year[187].

证券代码：688067 证券简称：爱威科技 编号：2022-001 爱威科技股份有限公司 投资者关系活动记录表 | --- | --- | --- | |--------------------------|-----------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------| | 投资者 \n关系活 \n动类别 | 特定对象调研 \n媒体采访 \n新闻发布会 \n现场参观 | 分析师会议 \n业绩说明会 \n路演活动 \n其他（电话会议） | | 时间 | 2022 年5月 10日 | 11:00-12:00 | | | 地点 上证路演中心网络互动 | | | | 董事长兼总经理：丁建文 | | | 公司接 待人员 姓名 | ...

2022 年第三季度报告 证券代码：688067 证券简称：爱威科技 一、 主要财务数据 (一)主要会计数据和财务指标 单位：元 币种：人民币 | 项目 | 本报告期 | 本报告期比 | | 年初至报告期 | | --- | --- | --- | --- | --- | | | | 上年同期增 | 年初至报告期末 | 末比上年同期 | | | | 减变动幅度 | | 增减变动幅度 | | | | (%) | | (%) | | 营业收入 | 56,997,836.51 | 3.11 | 150,477,680.38 | -1.38 | | 归属于上市公司股东的 | 11,915,935.05 | -19.83 | 23,863,197.98 | -13.16 | | 净利润 | | | | | | 归属于上市公司股东的 扣除非经常性损益的净 | 10,564,271.75 | -27.08 | 17,163,631.26 | -32.44 | | 利润 | | | | | 1 / 13 爱威科技股份有限公司 2022 年第三季度报告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者 重 ...

证券代码：688067 证券简称：爱威科技 公告编号：2022-032 爱威科技股份有限公司 关于参加湖南辖区上市公司 2022 年 投资者网上集体接待日活动的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 为进一步强化与投资者的互动交流，使广大投资者能更深入全面地了解公 司情况，爱威科技股份有限公司（以下简称"公司"）将参加由中国证券监督管 理委员会湖南监管局、湖南省上市公司协会与深圳市全景网络有限公司联合主 办的"湖南辖区上市公司 2022 年投资者网上集体接待日"活动，现将有关事项 公告如下： 本次投资者网上集体接待日活动将通过深圳市全景网络有限公司提供的互 联网平台，采用网络远程的方式举行。投资者可以登录"全景路演"网站 （http://rs.p5w.net/）参与公司本次投资者网上集体接待日活动。活动时间 为 2022 年 9 月 29 日（星期四）下午 15：30-16：55。 届时，公司董事会秘书及证券事务代表将通过网络文字形式与投资者进行 交流与沟通，欢迎广大投资者积极参与。 特此公告。 爱威科技股份 ...

Financial Performance - The company reported a total revenue of RMB 100 million for the first half of 2022, representing a year-on-year increase of 20%[1] - The company's revenue for the first half of 2022 was approximately ¥93.48 million, a decrease of 3.93% compared to ¥97.31 million in the same period last year[22] - The net profit attributable to shareholders for the first half of 2022 was approximately ¥11.95 million, down 5.30% from ¥12.62 million in the previous year[22] - The net profit attributable to shareholders after deducting non-recurring gains and losses was approximately ¥6.60 million, a significant decrease of 39.56% compared to ¥10.92 million in the same period last year[22] - The basic earnings per share for the first half of 2022 was ¥0.18, a decline of 28.00% from ¥0.25 in the previous year[20] - The diluted earnings per share also stood at ¥0.18, reflecting the same 28.00% decrease compared to the previous year[20] - The gross profit margin for the first half of 2022 was reported at 45%, an improvement from 40% in the same period last year[1] - The overall gross profit margin decreased from 58.91% in the previous year to 53.50% in the current reporting period[21] - The net cash flow from operating activities for the first half of 2022 was approximately ¥2.97 million, an increase of 5.77% from ¥2.81 million in the same period last year[22] Research and Development - The company has invested RMB 20 million in R&D for new technologies, focusing on machine vision and digital imaging[1] - The company's R&D expenditure accounted for 18.29% of operating revenue, an increase of 6.58 percentage points from 11.71% in the previous year[20] - Total R&D investment reached CNY 1,709.94 million, a significant increase of 50.12% compared to the same period last year[46] - The company employs a research and development strategy that emphasizes original innovation, aiming to continuously develop new products and technologies based on market demand[34] - The company has a total of 215 authorized patents, including 74 domestic invention patents and 12 overseas patents, as well as 23 software copyrights[42] - The company has completed the design and development of a COVID-19 antigen test kit, with clinical trial service fees capitalized at CNY 2,863,600.85[48] - The company has developed a range of automated medical inspection instruments, including urine, feces, and blood analysis devices, significantly improving inspection speed and accuracy[33] Market Expansion and Strategy - The company is expanding its market presence in Southeast Asia, targeting a 10% market share by the end of 2023[1] - The company is exploring potential acquisitions to strengthen its product portfolio and increase market competitiveness, with a budget of 500 million allocated for this purpose[110] - Strategic partnerships are being formed to enhance distribution channels, aiming to increase sales by 15% in the upcoming quarters[110] - The company is focused on the integration of artificial intelligence with medical testing, moving towards full laboratory automation and standardization[27] - The company is expanding its product offerings into the consumer medical testing market, launching various home-use POCT products, with some already achieving small-scale sales on e-commerce platforms[34] Risks and Challenges - The company has identified potential risks including regulatory changes and market competition, which are detailed in the risk factors section[1] - The company faced risks related to new product development, including potential delays in obtaining regulatory approvals, which could adversely affect market promotion[68] - The company is exposed to industry competition risks, with increasing competition from both domestic and international firms in the in vitro diagnostics market[71] - The company is at risk of losing key technical personnel, which could negatively impact new product development and core technology security[69] Compliance and Governance - No non-operational fund occupation by controlling shareholders was reported during the period[1] - The company strictly adheres to national environmental protection laws and regulations, ensuring compliance during production operations[88] - The company has signed contracts with third-party environmental agencies for the safe disposal of pollutants generated during production[88] - The company has committed to maintaining stock lock-up for 36 months post-IPO, ensuring stability in shareholding[91] - The company will ensure timely and accurate disclosure of information regarding any share reductions[95] Future Outlook - The company has provided a performance guidance for the second half of 2022, expecting a revenue growth of 25% year-on-year[1] - Future outlook includes continued investment in R&D to drive technological advancements and improve product offerings[39] - The company plans to strengthen internal controls and operational efficiency to mitigate risks and enhance decision-making processes[104] - The company is considering strategic acquisitions to bolster its market presence and diversify its product offerings[167]

Financial Performance - The company's operating revenue for 2021 was CNY 210,668,650.51, representing a year-on-year increase of 16.91% compared to CNY 180,199,388.49 in 2020[21]. - The net profit attributable to shareholders for 2021 was CNY 31,275,040.94, a 3.90% increase from CNY 30,100,264.86 in 2020[21]. - The net profit after deducting non-recurring gains and losses was CNY 23,985,348.09, which is a decrease of 9.14% from CNY 26,399,541.32 in 2020[21]. - The net cash flow from operating activities for 2021 was CNY 47,185,681.68, showing a slight increase of 0.54% from CNY 46,932,841.29 in 2020[21]. - The total assets at the end of 2021 were CNY 547,610,359.66, an increase of 84.65% compared to CNY 296,570,337.16 at the end of 2020[21]. - The net assets attributable to shareholders at the end of 2021 were CNY 477,579,653.02, reflecting a significant growth of 101.75% from CNY 236,719,197.28 at the end of 2020[21]. - The basic earnings per share for 2021 were CNY 0.53, a decrease of 10.17% from CNY 0.59 in 2020[22]. - The company's operating costs rose to RMB 86,611,317.38, reflecting an 18.19% increase from RMB 73,284,277.39 in the previous year[84]. - The gross profit margin for the main business was 58.81%, a decrease of 0.19 percentage points compared to the previous year[86]. Research and Development - The R&D expenditure as a percentage of operating revenue increased to 14.81% in 2021, up from 12.55% in 2020, indicating a focus on innovation[22]. - The company invested CNY 31.20 million in R&D, representing a year-on-year increase of 37.94%[31]. - The company has accumulated a vast clinical specimen image database over nearly 20 years, enhancing automatic recognition capabilities for various specimens[51]. - The company is focusing on the automation of medical testing, accumulating a series of core technologies through original innovation and technology integration[51]. - The company has developed key technologies in intelligent medical testing, particularly in automatic microscopy, filling a gap in the market for automated morphological testing[164]. Market Expansion and Strategy - The company plans to continue expanding its market presence and investing in new technologies to drive future growth[21]. - The company signed 7 new international agents in 2021, laying the groundwork for market expansion in the U.S.[30]. - The company aims to expand its product portfolio to meet the increasing demand for home healthcare, particularly in cancer screening and chronic disease monitoring[111]. - The marketing strategy includes expanding domestic and international channels, with a focus on increasing market share and brand recognition[113]. - The company is considering strategic acquisitions to enhance its product portfolio, with a budget of 100 million allocated for potential deals[129]. Corporate Governance - The company has established a scientific and standardized corporate governance structure in compliance with relevant laws and regulations[119]. - The company has not reported any significant changes in competition with its controlling shareholders or related parties[119]. - The company has not implemented any differential voting rights arrangements during the reporting period[124]. - The governance structure complies with the regulations set forth by the China Securities Regulatory Commission[119]. - The company has a clear process for the appointment and remuneration of its directors and supervisors, ensuring transparency and accountability[135]. Risks and Challenges - The company has not achieved profitability since its listing[4]. - The company faces risks related to product price declines due to rapid technological advancements and government pricing regulations in clinical testing[78]. - The ongoing COVID-19 pandemic has led to a decrease in hospital visits, negatively affecting the demand for the company's reagent consumables[81]. - The company has a risk of losing key technical personnel, which could adversely affect its R&D capabilities[78]. - The competitive landscape in the in vitro diagnostics market has intensified, with both domestic and international companies increasing their market share[80]. Social Responsibility and Environmental Initiatives - The company actively engages in social responsibility initiatives, focusing on health technology and improving human health standards[164]. - The company has implemented measures to reduce carbon emissions and improve energy efficiency, including the use of high-efficiency energy-saving equipment[159][160]. - The company has a comprehensive waste management system, ensuring proper recycling and disposal of solid waste[162]. - In December 2021, the company donated 80,000 yuan to the Hunan Women's and Children's Development Foundation[168]. - The company contributed 24,600 yuan to public welfare projects in December 2021, assisting vocational school students in difficult family situations[168]. Shareholder Information - The proposed cash dividend distribution is RMB 3.00 per 10 shares, totaling RMB 20,400,000.00, which accounts for 65.23% of the net profit attributable to shareholders for 2021[5]. - The total share capital as of December 31, 2021, is 68,000,000 shares[5]. - The company has not reported any significant reliance on a single customer or supplier, indicating a diversified customer and supplier base[97][98]. - The company has a total of 18 employees holding shares, representing 3.54% of the total workforce[171]. - Employee shareholding amounts to 3,651,000 shares, accounting for 53.69% of the total share capital[171].

Financial Performance - The company's operating revenue for Q1 2022 was ¥46,075,955.93, representing a decrease of 2.46% compared to the same period last year[6]. - The net profit attributable to shareholders was ¥5,838,880.44, down 11.17% year-on-year[6]. - The net profit after deducting non-recurring gains and losses was ¥4,059,432.08, a decline of 27.08% compared to the previous year[6]. - The basic earnings per share (EPS) was ¥0.09, reflecting a decrease of 30.77% year-on-year[7]. - In Q1 2022, the company's net profit was CNY 5,838,880.44, a decrease of 11.2% compared to CNY 6,573,200.38 in Q1 2021[22]. - The total comprehensive income for Q1 2022 was CNY 5,836,557.12, a decrease from CNY 6,566,645.85 in Q1 2021[22]. - The company reported a tax expense of CNY 239,002.90 in Q1 2022, down from CNY 421,607.38 in Q1 2021, indicating a decrease of 43.3%[21]. Research and Development - Research and development (R&D) expenses totaled ¥6,117,372.00, an increase of 11.70% from the previous year, accounting for 13.28% of operating revenue, up 1.69 percentage points[7]. - Research and development expenses rose to CNY 6,117,372.00 in Q1 2022, compared to CNY 5,476,814.49 in Q1 2021, marking an increase of 11.7%[21]. Cash Flow and Assets - The net cash flow from operating activities was negative at -¥2,965,689.40, indicating significant changes in cash flow dynamics[6]. - Cash and cash equivalents decreased to CNY 69,912,698.66 from CNY 228,283,712.91 as of December 31, 2021, representing a decline of 69.4%[16]. - The company reported a net cash outflow from operating activities of CNY -2,965,689.40 in Q1 2022, an improvement from CNY -10,916,337.35 in Q1 2021[24]. - The company generated CNY 51,689,439.55 in cash from sales in Q1 2022, an increase of 25.8% from CNY 41,060,534.70 in Q1 2021[24]. - Investment activities resulted in a net cash outflow of CNY -155,404,537.56 in Q1 2022, compared to a net inflow of CNY 16,330,965.03 in Q1 2021[25]. Assets and Liabilities - The total assets at the end of the reporting period were ¥544,623,374.05, a decrease of 0.55% from the end of the previous year[7]. - Total current assets amounted to CNY 348,277,622.52, slightly down from CNY 353,432,220.35, a decrease of 1.5%[16]. - Total liabilities decreased to CNY 60,666,747.23 from CNY 70,030,706.64, a decline of 13.5%[18]. - Total assets as of March 31, 2022, were CNY 544,623,374.05, down from CNY 547,610,359.66, a decrease of 0.5%[18]. - Non-current assets increased to CNY 196,345,751.53 from CNY 194,178,139.31, an increase of 1.1%[17]. - Total equity attributable to shareholders increased to CNY 483,956,626.82 from CNY 477,579,653.02, an increase of 1.8%[18]. - Inventory increased to CNY 46,407,323.90 from CNY 43,597,527.41, an increase of 6.4%[17]. Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 4,111[12]. - The company reported a total of 10 major shareholders, with the largest shareholder holding 1,700,000 shares[14].

2021 年第三季度报告 一、 主要财务数据 主要会计数据和财务指标 (一)主要会计数据和财务指标 证券代码：688067 证券简称：爱威科技 爱威科技股份有限公司 2021 年第三季度报告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者 重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 公司董事会、监事会及董事、监事、高级管理人员保证季度报告内容的真实、准确、完整， 不存在虚假记载、误导性陈述或重大遗漏，并承担个别和连带的法律责任。 公司负责人、主管会计工作负责人及会计机构负责人（会计主管人员）保证季度报告中财务 报表信息的真实、准确、完整。 第三季度财务报表是否经审计 □是 √否 单位：元 币种：人民币 | 项目 | 本报告期 | 本报告期比 上年同期增 | 年初至报告期末 | 年初至报告期 末比上年同期 | | --- | --- | --- | --- | --- | | | | 减变动幅度 | | 增减变动幅度 | | | | (%) | | (%) | | 营业收入 | 55,279,669.95 | 19.66 | 152,588,122.6 ...

证券代码：688067 证券简称：爱威科技 公告编号：2021-017 爱威科技股份有限公司 关于参加 2021 年湖南辖区上市公司 投资者网上集体接待日活动的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 为进一步强化与投资者的互动交流，使广大投资者能更深入全面地了解公 司情况，爱威科技股份有限公司（以下简称"公司"）将参加由中国证券监督管 理委员会湖南监管局举办、湖南省上市公司协会与深圳市全景网络有限公司协 办的"2021 年湖南辖区上市公司投资者网上集体接待日"活动，现将有关事项 公告如下： 本次投资者网上集体接待日活动将通过深圳市全景网络有限公司提供的互 联网平台，采用网络远程的方式举行。投资者可以登录"全景·路演天下"网 站（http://rs.p5w.net/）参与公司本次投资者网上集体接待日活动。活动时 间为 2021 年 9 月 24 日（星期五）15：00-17：00。 届时，公司董事会秘书及证券事务代表将通过网络文字形式与投资者进行 交流与沟通，欢迎广大投资者积极参与。 特此公告。 爱威科技股份有 ...